What is the recommended management for drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)?

Management of DRESS Syndrome

Immediately discontinue the suspected causative drug, initiate systemic corticosteroids, and hospitalize the patient for close monitoring of multi-organ involvement.

Immediate Actions

Drug Discontinuation

• Identify and permanently stop the offending medication immediately – this is the single most critical intervention for DRESS syndrome 1, 2.
• Common culprits include anticonvulsants (lamotrigine, phenytoin, carbamazepine), antibiotics (especially sulfonamides), allopurinol, and antiretrovirals (abacavir, nevirapine) 1, 3.
• Do not rechallenge with the suspected drug, as this can be fatal 1.

Emergency Hospitalization

• Admit all patients with suspected DRESS to the hospital immediately for intensive monitoring and management 1.
• Severe cases (Grade 3-4) require ICU admission or burn unit consultation, particularly when extensive skin involvement or multi-organ failure is present 1.

Diagnostic Workup

Essential Laboratory Testing

• Complete blood count with differential to assess for eosinophilia (typically >1000 cells/μL or >10%) and atypical lymphocytosis 2, 3.
• Comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin) and renal function (creatinine, BUN) 1, 2.
• Urinalysis to evaluate for nephritis, particularly in the context of systemic involvement 1.
• Blood cultures if fever is present to rule out infectious etiology 1.

Additional Investigations Based on Severity

• Chest imaging if pulmonary symptoms are present (pneumonitis occurs in some cases) 4, 3.
• Echocardiography if cardiac involvement is suspected (myocarditis, pericarditis) 1.
• Viral serologies for herpesvirus reactivation (HHV-6, EBV, CMV) may be considered, as viral reactivation is part of DRESS pathophysiology 4, 5.
• Skin biopsy can support diagnosis but should not delay treatment; shows interface dermatitis with eosinophils and atypical lymphocytes 1.

Severity Assessment

Grading System

Mild DRESS: Cutaneous eruption with fever and eosinophilia, minimal organ involvement, liver enzymes <5× upper limit of normal 2.

Moderate DRESS: More extensive skin involvement (>50% body surface area), liver enzymes 5-10× upper limit of normal, or mild renal impairment 2.

Severe DRESS: Extensive skin detachment, liver enzymes >10× upper limit of normal, acute kidney injury requiring intervention, or involvement of other organs (heart, lungs) 2.

Pharmacological Management

Systemic Corticosteroids (First-Line)

• For Grade 3-4 or moderate-to-severe DRESS: Start IV methylprednisolone 1-2 mg/kg/day (or equivalent prednisone dose if oral intake is tolerated) 1.
• For milder cases: Oral prednisone 0.5-1 mg/kg/day may be sufficient 1.
• Taper slowly over 4-6 weeks minimum once clinical improvement occurs and laboratory abnormalities normalize 1.
• Premature steroid withdrawal can lead to disease flare, which occurs in up to 12% of cases 1, 2.

Supportive Care

• Topical emollients and high-potency topical corticosteroids for skin lesions 1.
• Oral antihistamines for pruritus management 1.
• Proton pump inhibitor for gastrointestinal prophylaxis during corticosteroid therapy 1.
• Pneumocystis jirovecii pneumonia (PCP) prophylaxis if prolonged immunosuppression (>3 weeks at >30 mg prednisone equivalent/day) is anticipated 1.

Second-Line Therapies for Steroid-Resistant Cases

• Intravenous immunoglobulin (IVIG) at 2 g/kg divided over 3-5 days for patients not responding to corticosteroids within 2-3 days 1, 5.
• Cyclosporine (3-5 mg/kg/day) as an alternative immunosuppressant for refractory cases 1, 5.
• Cyclophosphamide has been used in severe, treatment-resistant cases 5, 6.
• N-acetylcysteine may be considered, particularly for hepatotoxicity 6.
• Plasmapheresis has been reported in isolated severe cases 5.

Emerging Therapies

• Biologics (such as dupilumab, mepolizumab) and JAK inhibitors have shown promise in case reports but lack robust evidence 5.

Dermatology and Specialist Consultation

• Immediate dermatology consultation is mandatory for all suspected DRESS cases 1.
• Burn unit or wound care consultation for extensive skin involvement or blistering 1.
• Ophthalmology, otolaryngology, urology, or gynecology consultations if mucous membrane involvement is present to prevent scarring sequelae 1.
• Hepatology consultation for severe hepatic involvement 2.

Critical Pitfalls to Avoid

Do Not Confuse with Stevens-Johnson Syndrome/TEN

• While both are severe cutaneous adverse reactions, DRESS typically has later onset (2-6 weeks vs. 1-3 weeks for SJS/TEN), more prominent systemic features (eosinophilia, organ involvement), and facial edema is characteristic (present in 44% of DRESS cases) 3.
• Unlike classic SJS/TEN, corticosteroids ARE indicated for DRESS because the underlying mechanism is T-cell immune-directed toxicity 1.

Recognize Delayed Onset and Prolonged Course

• DRESS symptoms typically appear 14-60 days after drug initiation, much later than most drug reactions 4, 3.
• The syndrome can persist or relapse for weeks to months even after drug discontinuation due to viral reactivation and immune dysregulation 1, 4, 2.

Monitor for Late Complications

• Autoimmune sequelae (thyroiditis, type 1 diabetes, lupus) can develop months after acute DRESS resolution in up to 10% of patients 2, 7.
• Long-term follow-up for at least 6-12 months is essential with periodic thyroid function tests and monitoring for autoimmune manifestations 2, 7.

Post-Acute Management

Follow-Up Monitoring

• Serial laboratory monitoring (CBC, liver function, renal function) weekly initially, then monthly during steroid taper 2.
• Thyroid function testing at 3,6, and 12 months post-resolution to detect autoimmune thyroiditis 2, 7.
• Screen for other autoimmune conditions if new symptoms emerge 7.

Allergological Workup

• Patch testing or delayed intradermal testing should be deferred until at least 6 months after resolution and after discontinuation of systemic corticosteroids for >1 month to avoid false negatives and potential viral reactivation 1.
• Never rechallenge with the culprit drug based on negative skin testing alone, as the negative predictive value is imperfect 1.
• Testing may help identify cross-reactive drugs to avoid in the future 1.

Prognosis

• Mortality rate is approximately 9-10% in reported case series, with allopurinol associated with higher mortality (23% of fatal cases) 3.
• Early recognition, prompt drug withdrawal, and appropriate corticosteroid therapy significantly improve outcomes 2, 3.
• Most patients recover fully with appropriate management, but prolonged immunosuppression may be required 2, 5.